191 related articles for article (PubMed ID: 23410508)
1. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.
Sumbria RK; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Mol Pharm; 2013 Apr; 10(4):1425-31. PubMed ID: 23410508
[TBL] [Abstract][Full Text] [Related]
2. Brain-penetrating tumor necrosis factor decoy receptor in the mouse.
Zhou QH; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2011 Jan; 39(1):71-6. PubMed ID: 20884844
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
[TBL] [Abstract][Full Text] [Related]
4. Brain protection from stroke with intravenous TNFα decoy receptor-Trojan horse fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1933-8. PubMed ID: 22714051
[TBL] [Abstract][Full Text] [Related]
5. Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice.
Yang J; Sun J; Castellanos DM; Pardridge WM; Sumbria RK
Mol Pharm; 2020 Aug; 17(8):2831-2839. PubMed ID: 32579360
[TBL] [Abstract][Full Text] [Related]
6. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.
Sumbria RK; Boado RJ; Pardridge WM
Brain Res; 2013 Apr; 1507():91-6. PubMed ID: 23428543
[TBL] [Abstract][Full Text] [Related]
7. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
9. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
10. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
J Biotechnol; 2010 Mar; 146(1-2):84-91. PubMed ID: 20100527
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
[TBL] [Abstract][Full Text] [Related]
14. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2012 Feb; 40(2):329-35. PubMed ID: 22065691
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2011 Jan; 1369():203-7. PubMed ID: 21047502
[TBL] [Abstract][Full Text] [Related]
16. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein.
Zhou QH; Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2011 Aug; 22(8):1611-8. PubMed ID: 21707084
[TBL] [Abstract][Full Text] [Related]
17. Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice.
Sun J; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2019 Aug; 16(8):3534-3543. PubMed ID: 31199881
[TBL] [Abstract][Full Text] [Related]
18. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
Pardridge WM
Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
[TBL] [Abstract][Full Text] [Related]
19. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein.
Boado RJ; Hui EK; Lu JZ; Zhou QH; Pardridge WM
Mol Pharm; 2011 Aug; 8(4):1342-50. PubMed ID: 21667973
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
Hui EK; Boado RJ; Pardridge WM
Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]